Genetic inactivation of the neuron-specific isoform, JNK3, ameliorates the disease phenotype in SMA mice without affecting SMN protein levels, indicating that JNK3 may represent a promising SMN-independent target for pharmacological intervention. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.